Jump to content

User talk:PageMaster

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by PageMaster (talk | contribs) at 21:50, 29 November 2017 (→‎Notice of Edit warring noticeboard discussion). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Welcome

Hello, PageMaster, and Welcome to Wikipedia!

Welcome to Wikipedia! I hope you enjoy the encyclopedia and want to stay. As a first step, you may wish to read the Introduction.

If you have any questions, feel free to ask me at my talk page – I'm happy to help. Or, you can ask your question at the New contributors' help page.


Here are some more resources to help you as you explore and contribute to the world's largest encyclopedia...

Finding your way around:

Need help?

How you can help:

Additional tips...

PageMaster, good luck, and have fun. — JJMC89(T·C) 22:51, 5 November 2017 (UTC)[reply]


PageMaster says:

I am retired from the telephone company after 35 years. I do not have any connection with Efranat Ltd. I learned about GcMAF from browsing the internet. I became greatly interested in the subject and began reading everything I could find about it. This was a few years back. I read the Wikipedia listing for GcMAF and knew it was wrong because the human immune system makes it for a purpose. The human body is very efficient and does not waste energy on something (GcMAF) it does not need or use. The more I learned the more I became convinced that the human immune system used its GcMAF to fight diseases. So I decided to try it (GOleic) to prevent prostate cancer. I believe the paper published by Dr. Yamamoto on prostate cancer was never retracted despite efforts to get it retracted. But anyway, I was pleased with the results I got when using GOleic in spite of the negative press on it. In case you do not know GOleic is a legal supplement in Germany and is an injectable GcMAF product with Oleic Acid and Saline. So any hint that I have a conflict of interest is absurd. I just know more about GcMAF than most of you. Also since the Wikipedia listing for GcMAF is now mostly wrong and out of date, I am trying to provide current information to show its evolution. There is no question that Efranat Ltd is developing GcMAF as a new cancer cure and for viral diseases. We all need to follow this for our own sake. The general public does not need to be afraid of GcMAF.

Remember this article should discuses just the science of GcMAF. It references Efranat Ltd because they are the ones who performed a Phase 1 Clinical Trial using terminal cancer patients with an all natural substance. No one else has ever done this. This is very rare and practically unheard of for an all natural substance. GcMAF itself cannot be patented. The world needs to know that GcMAF is NOT all bad and I intend to make this known if the science department at Wikipedia is not run by a bunch of pharmaceutical shills.

Also your approved posting for GcMAF includes a reference to Efranat Ltd on this page. You did not ask them to justify why they mentioned Efranat Ltd in the same context as GcMAF. Double standard?

PageMaster (talk) 02:38, 9 November 2017 (UTC)[reply]

Conflict of interest in Wikipedia

Hi PageMaster. I work on conflict of interest issues here in Wikipedia, along with my regular editing, which is mostly about health and medicine. Your edits to date are promotional with regard to Efranat. I'm giving you notice of our Conflict of Interest guideline and Terms of Use, and will have some comments and requests for you below.

Information icon Hello, PageMaster. We welcome your contributions, but if you have an external relationship with the people, places, or things you have written about on Wikipedia, you may have a conflict of interest (COI). Editors with a COI may be unduly influenced by their connection to the topic, and it is important when editing Wikipedia articles that such connections be completely transparent. See the conflict of interest guideline and FAQ for organizations for more information. In particular, we ask that you please:

  • avoid editing or creating articles related to you and your family, friends, school, company, club, or organization, as well as any competing companies' projects or products;
  • instead, you are encouraged to propose changes on the Talk pages of affected article(s) (see the {{request edit}} template);
  • when discussing affected articles, disclose your COI (see WP:DISCLOSE);
  • avoid linking to the Wikipedia article or to the website of your organization in other articles (see WP:SPAM);
  • exercise great caution so that you do not violate Wikipedia's content policies.

In addition, you must disclose your employer, client, and affiliation with respect to any contribution which forms all or part of work for which you receive, or expect to receive, compensation (see WP:PAID).

Please take a few moments to read and review Wikipedia's policies regarding conflicts of interest, especially those pertaining to neutral point of view, sourcing and autobiographies.

Also please note that editing for the purpose of advertising, publicising, or promoting anyone or anything is not permitted. Thank you.

Comments and requests

Wikipedia is a widely-used reference work and managing conflict of interest is essential for ensuring the integrity of Wikipedia and retaining the public's trust in it. As in academia, COI is managed here in two steps - disclosure and a form of peer review. Please note that there is no bar to being part of the Wikipedia community if you want to be involved in articles where you have a conflict of interest; there are just some things we ask you to do (and if you are paid, some things you need to do).

Disclosure is the most important, and first, step. While I am not asking you to disclose your identity (anonymity is strictly protecting by our WP:OUTING policy) would you please disclose if you have some connection with Efranat, directly or through a third party (e.g. a PR agency or the like)? You can answer how ever you wish (giving personally identifying information or not), but if there is a connection, please disclose it, and if that connection includes being paid to edit, please make sure you disclose that too. After you respond (and you can just reply below), I can walk you through how the "peer review" part happens and then, if you like, I can provide you with some more general orientation as to how this place works. Please reply here, just below, to keep the discussion in one place. Thanks! Jytdog (talk) 00:49, 9 November 2017 (UTC)[reply]

Spam warning efranat.com

Stop icon You may be blocked from editing without further warning the next time you insert a spam link. Persistent spammers may have their websites blacklisted, preventing anyone from linking to them from all Wikimedia sites as well as potentially being penalized by search engines. Jytdog (talk) 04:22, 9 November 2017 (UTC)[reply]

A tag has been placed on User:PageMaster requesting that it be speedily deleted from Wikipedia. This has been done under section U5 of the criteria for speedy deletion, because the page appears to consist of writings, information, discussions, and/or activities not closely related to Wikipedia's goals. Please note that Wikipedia is not a free web hosting service. Under the criteria for speedy deletion, such pages may be deleted at any time.

If you think this page should not be deleted for this reason, you may contest the nomination by visiting the page and clicking the button labelled "Contest this speedy deletion". This will give you the opportunity to explain why you believe the page should not be deleted. However, be aware that once a page is tagged for speedy deletion, it may be deleted without delay. Please do not remove the speedy deletion tag from the page yourself, but do not hesitate to add information in line with Wikipedia's policies and guidelines. If the page is deleted, and you wish to retrieve the deleted material for future reference or improvement, then please contact the deleting administrator, or if you have already done so, you can place a request here. John from Idegon (talk) 04:52, 9 November 2017 (UTC)[reply]

Contested deletion

This page should not be speedily deleted because... (your reason here) --PageMaster (talk) 06:05, 9 November 2017 (UTC)[reply]

It contains valid and up-to-date information on the subject of GcMAF. The old post is misleading and out of date. It infers that further development of GcMAF is dead. This is incorrect. GcMAF is being developed in Israel by Efranat Ltd. The old post does not mention that a successful FDA registered Phase 1 Clinical Trial has COMPLETED on GcMAF. The old post infers that GcMAF has never gone through any formal clinical trials and has not been proven safe. This is incorrect now. The old post does not reference the results of this official completed clinical trial. The old post does not mention that GcMAF is now being looked at by the FDA and Efranat Ltd as a new treatment for RPP. I stand by my references and submit that they are reputable and reliable.

I am a newbie to Wikipedia and just started posting on GcMAF which is my specialty (no conflicts of interest). I did not delete the old post, just added to bring the information up to date. Then these 2 old timers jumped on me without me knowing really why. They did not question my information. ScienceWatcher did initially because I did not reference my information correctly. I corrected that and ScienceWatcher restored by corrected post. Look at the history and you will see that. I am willing to discuss the status and science of GcMAF with anyone, but these 2 old timers don't seem to be interested in the science. They don't want the GcMAF information up-dated for some unknown reason. I welcome this review so the truth can come out.

P.S. - I think these old timers think they can do me in quickly because I don't know all the rules yet. They are probably thinking I would not know to respond to this tag. They need a good talking too. Someone needs to find out why they oppose the truth on GcMAF.


PageMaster (talk) 06:05, 9 November 2017 (UTC)[reply]

You said the following, "I am a newbie to Wikipedia and just started posting on GcMAF which is my specialty (no conflicts of interest)." please could you explain how you are a specialist, and why you have no WP:COI. Thanks. -Roxy the dog. bark 12:29, 9 November 2017 (UTC)[reply]

November 2017

Stop icon with clock
You have been blocked from editing for a period of 24 hours for edit warring, as you did at GcMAF. Once the block has expired, you are welcome to make useful contributions.
During a dispute, you should first try to discuss controversial changes and seek consensus. If that proves unsuccessful, you are encouraged to seek dispute resolution, and in some cases it may be appropriate to request page protection.
If you think there are good reasons for being unblocked, please read the guide to appealing blocks, then add the following text below the block notice on your talk page: {{unblock|reason=Your reason here ~~~~}}.  — Martin (MSGJ · talk) 13:59, 9 November 2017 (UTC)[reply]

Your submission at Articles for creation: sandbox (November 13)

Your recent article submission to Articles for Creation has been reviewed! Unfortunately, it has not been accepted at this time. The reason left by Sulfurboy was: Please check the submission for any additional comments left by the reviewer. You are encouraged to edit the submission to address the issues raised and resubmit when they have been resolved.
Sulfurboy (talk) 20:28, 13 November 2017 (UTC)[reply]


Teahouse logo
Hello! PageMaster, I noticed your article was declined at Articles for Creation, and that can be disappointing. If you are wondering why your article submission was declined, please post a question at the Articles for creation help desk. If you have any other questions about your editing experience, we'd love to help you at the Teahouse, a friendly space on Wikipedia where experienced editors lend a hand to help new editors like yourself! See you there! Sulfurboy (talk) 20:28, 13 November 2017 (UTC)[reply]